Omada Health, Inc. Research and Development Expense
Omada Health, Inc. (OMDA) reported Research and Development Expense of $14.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Omada Health, Inc. research and development expense for the quarter ending 2026-06-30 was $14.63M, a 45.90% increase year-over-year.
- Omada Health, Inc. research and development expense for the quarter ending 2026-03-31 was $12.70M, a 44.19% increase year-over-year.
- Omada Health, Inc. research and development expense for the quarter ending 2025-12-31 was $11.55M, a 25.70% increase year-over-year.
- Omada Health, Inc. research and development expense for the quarter ending 2025-09-30 was $10.30M, a 16.40% increase year-over-year.
- Omada Health, Inc. research and development expense for fiscal 2025 was $40.68M, a 13.25% increase from fiscal 2024.
- Omada Health, Inc. research and development expense for fiscal 2024 was $35.92M, a 6.48% increase from fiscal 2023.
- Omada Health, Inc. research and development expense for fiscal 2023 was $33.74M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.63M 10-Q · filed 2026-08-07 | $27.32M 10-Q · filed 2026-08-07 | $38.87M derived: sum of 3 quarters · filed 2026-08-07 | $49.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $12.70M 10-Q · filed 2026-05-08 | $24.25M derived: sum of 2 quarters · filed 2026-05-08 | $34.55M derived: sum of 3 quarters · filed 2026-05-08 | $44.57M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $21.85M derived: sum of 2 quarters · filed 2026-03-06 | $31.88M derived: sum of 3 quarters · filed 2026-08-07 | $40.68M 10-K · filed 2026-03-06 |
| 2025-09-30 | $10.30M 10-Q · filed 2025-11-07 | $20.32M derived: sum of 2 quarters · filed 2026-08-07 | $29.13M 10-Q · filed 2025-11-07 | $38.32M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $10.02M 10-Q · filed 2026-08-07 | $18.83M 10-Q · filed 2026-08-07 | $28.02M derived: sum of 3 quarters · filed 2026-08-07 | $36.87M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $8.81M 10-Q · filed 2026-05-08 | $18.00M derived: sum of 2 quarters · filed 2026-05-08 | $26.85M derived: sum of 3 quarters · filed 2026-05-08 | $35.83M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $18.04M derived: sum of 2 quarters · filed 2026-03-06 | $27.03M derived: sum of 3 quarters · filed 2026-03-06 | $35.92M 10-K · filed 2026-03-06 |
| 2024-09-30 | $8.85M 10-Q · filed 2025-11-07 | $17.84M derived: sum of 2 quarters · filed 2025-11-07 | $26.73M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $8.99M 10-Q · filed 2025-08-08 | $17.88M 10-Q · filed 2025-08-08 | ||
| 2023-12-31 | $33.74M 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |